Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
1995-12-7
|
| pubmed:abstractText |
Two proposed mechanisms of diabetic neuropathy are microvascular ischaemia and a reduction in Na,K-ATPase activity. We evaluated the effect of cilostazol, a drug that is both a potent phosphodiesterase inhibitor that normalizes nerve Na,K-AT-Pase and a vasodilator, on nerve blood flow (NBF) to determine whether it would improve experimental diabetic neuropathy. We examined whether epineurally applied cilostazol acted as a vasodilator on the peripheral nerve of normal and diabetic rats, and whether feeding the rats a cilostazol-supplemented diet could improve diabetic neuropathy. Cilostazol increased nerve blood flow (NBF) in a dose-dependent fashion with an EC50 of 10(-5.74) mol/l. Cilostazol also normalized NBF in experimental diabetic neuropathy with a 10(-4) mol/l local application on the sciatic nerve. In diabetic neuropathy, a cilostazol-supplemented diet improved both NBF and nerve conduction in a dose- and time-dependent fashion. Potential mechanisms of action of cilostazol on the nerve include its effect on NBF, Na, K-ATPase, and restoration of the thromboxane:prostacyclin ratio. Cilostazol may have potential in the treatment of diabetic neuropathy.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphodiesterase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Vasodilator Agents,
http://linkedlifedata.com/resource/pubmed/chemical/cilostazol
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0012-186X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
38
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
914-8
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:7589876-Animals,
pubmed-meshheading:7589876-Blood Glucose,
pubmed-meshheading:7589876-Blood Pressure,
pubmed-meshheading:7589876-Body Weight,
pubmed-meshheading:7589876-Diabetes Mellitus, Experimental,
pubmed-meshheading:7589876-Diabetic Neuropathies,
pubmed-meshheading:7589876-Food, Fortified,
pubmed-meshheading:7589876-Male,
pubmed-meshheading:7589876-Neural Conduction,
pubmed-meshheading:7589876-Peripheral Nerves,
pubmed-meshheading:7589876-Phosphodiesterase Inhibitors,
pubmed-meshheading:7589876-Rats,
pubmed-meshheading:7589876-Rats, Sprague-Dawley,
pubmed-meshheading:7589876-Regional Blood Flow,
pubmed-meshheading:7589876-Sciatic Nerve,
pubmed-meshheading:7589876-Tetrazoles,
pubmed-meshheading:7589876-Tibial Nerve,
pubmed-meshheading:7589876-Vasodilator Agents
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Effect of cilostazol on experimental diabetic neuropathy in the rat.
|
| pubmed:affiliation |
Department of Neurology, Mayo Foundation, Rochester, Minnesota 55905, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|